Navigation Links
GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting

in the Phase III ADT clinical trial.

-- "Prevalence of osteoporosis and osteopenia during androgen deprivation therapy (ADT) for prostate cancer: Baseline data from a large randomized controlled trial." Poster number: F5. Abstract number: 5116.

-- Date and time: June 3, 2007 from 2:00 to 6:00 p.m.

-- Location: S Hall A2

About GTx

GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE(R). GTx also is developing Ostarine(TM), a first-in-class selective androgen receptor modulator, or SARM. GTx plans to initiate a Phase IIb Ostarine(TM) clinical trial for cancer cachexia in non-small cell lung cancer patients in June of 2007. GTx plans to initiate a Phase IIb Ostarine(TM) clinical trial for the treatment of chronic kidney disease muscle wasting by the end of 2007. GTx believes that Ostarine(TM) also has the potential to treat a variety of other indications associated with muscle wasting and bone loss including sarcopenia and osteoporosis.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertaint
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:10/10/2008)...0 /- Inverness Medical,Inno... near-patient,diagnostics, monitoring and health m...n, the Secretary-General of the United Nations, as... of the world,s leading,research-based and generic...s, together with senior officials from the United ...
(Date:10/9/2008)...reased Sales and Marketing Efforts to Accelerate ...tem, MENLO PARK, Calif., Oct. 9 /- E...ces for the percutaneous repair of cardiac valves,...am with the appointment of,Sean Cleary as senior v...,Chris Richardson, as vice president of sales., "...
(Date:10/8/2008)... Animal Use in Cosmetics and Chemicals Testing, A... today announced,that results of a recently comple...lidation study on MatTek,s EpiDerm in vitro human ...ted the required sensitivity and,specificity for E...o animal,testing for determining human skin irrita...
(Date:10/8/2008)...o evaluate TAXUS(R) Element(TM) Platinum Chromium ...ss., Oct. 8 /- Boston Scien...at it has completed enrollment in,the PERSEUS tria...tion,TAXUS(R) Element(TM) paclitaxel-eluting coron...ed nearly 1,500 patients at 100 U.S. and,internati...
Breaking Medicine Technology:Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Best Practice Database Supports Bio Pharma M 26A Integration with New Publication 21393 1Best Practice Database Supports Bio Pharma M 26A Integration with New Publication 21393 2Golf cart injuries on the rise 21391 1Golf cart injuries on the rise 21391 2Video 3A The Nevada Division of Insurance Launches 2008 Health Sham Insurance Campaign 21390 1Video 3A The Nevada Division of Insurance Launches 2008 Health Sham Insurance Campaign 21390 2Video 3A The Nevada Division of Insurance Launches 2008 Health Sham Insurance Campaign 21390 3N Y Mets Omar Minaya Recognized at National Brain Cancer Organizations 3rd Annual Gala 21385 1N Y Mets Omar Minaya Recognized at National Brain Cancer Organizations 3rd Annual Gala 21385 2
...ion Pharmaceuticals Inc.,(TSX: TLN) announced toda...al trial investigating ECO-4601 in advanced cancer...f the American,Society of Clinical Oncology (ASCO)... I dose escalation portion of the study, 14,patien...one,glioma), that had completed and not responded ...
...- Imprime PGG(TM), an,investigational new drug fro...response, increases the effectiveness of Avastin(R... new preclinical,research presented yesterday at t...al Meeting in Chicago., Researchers at the Brown C...studied the synergistic effects of Imprime,PGG in ...
Other Medicine Technology:Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3Biothera's Imprime PGG Enhanced Effectiveness of Avastin in Cancer,Study 2
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...e of the African naked mole-rat is helping scienti...in humans. Mole-rats are blind, hairless, and li...led over by a queen. In a new study, scientists, ...atures, are hoping to learn more about how stress ...
...ened to nationalise private hospitals if their own... a nationally televised speech, saying that the pr...part of the public health service if they failed t...e also described costs at private clinics as a sym...
... the knot-like structure of enzymes, but theyve be... an understanding of function what the enzyme act...drug discovery, since many of the most successful .... Now, in an expedited article in NATURE, research...
...ped by methane gas is commonplace in developing co... West too. Fiver persons fell victims to the deadl...arm in Shenandoah Valley, Virginia, US Monday even...34, a Mennonite farmer who climbed into the pit to...
Other Medicine News:Health News:Strange Sex Life of Mole-rats may Provide Clues About Human Infertility 2Health News:Translating Structure into Function 2Health News:Five Killed by Methane Gas on Virginia Farm 2Health News:Five Killed by Methane Gas on Virginia Farm 3
The Affinity pacemaker family offers some of today's smallest, truly automatic devices. Featuring the most effective combination of advanced technologies ever seen, the Affinity DR pacemaker incorpor
Innovative new tools for more efficient patient management begin when the pacemaker is implanted. These sophisticated tools are in effect each day, and they help automate follow-up tasks.
The first-ever completely automatic pacemaker, EnPulse offers exclusive features that make it sophisticated yet simple to use. It performs a wide range of diagnostic tests on a regular basis, without
...ystem 3000Dx (GCS3000Dx) is the first microarray i...oratories. The system consists of the FS450Dx Flui...g and staining of the array, the GCS3000Dx Scanner...croarrays to be scanned without operator intervent...
Medicine Products: